OCEAN(a) CCTA
A Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Safety, Tolerability, and Effect of Olpasiran on Coronary Artery Plaque Burden Assessed by Coronary Computed Tomography Angiography in Participants With Stable Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)”
- Stage
- inclusie
- Medicine
- Olpasiran
- Population
- Primaire preventie coronairlijden
- Phase
- III
- First Patient In
- 1 May 2026
- Last Patient In
- 12 December 2026
- Last Patient Last Visit
- 19 May 2028